Tag
The European Union has some 20 "biosimilar" generics on the market; the US has one.
Hedge funds are joining groups who want to lower prescription prices for consumers.
The company's CEO stepped down on Monday
A new report suggests drug makers are profiting from the waste.
Its Caremark unit covers some 25 million U.S. customers
The industry worries it's a step toward price controls.
More generics are needed to create competition — but can the FDA approve them fast enough?
It's not just a few bad players, as Congressional hearing puts drug costs in focus.
This may actually lower drug costs.
The push comes even as lawmakers discuss ways to rein in drug prices.
